Jag Shur

Dr Shur is an academic and entrepreneur having over 100 published scientific papers and was CEO of Nanopharm Ltd, which he led to a successful exit in 2019. Jag’s main area of research and commercial endeavour is in the complex topical pharmaceutical drug products area. A key theme of his research and commercial enterprises have been to develop patient-centric drug development platforms. He began his career with Profile Drug Delivery (now Philips Respironics) where he developed liquid dose drug delivery systems for cystic fibrosis patients, and later went on to work for GlaxoSmithKline. Jag holds a BSc (Hons) in Chemistry and completed his PhD, entitled ‘Formulated Muco-Regulatory Agents in the Airways of Patients with Cystic Fibrosis’. Following this, he was a post-doctoral fellow at the London School of Pharmacy, investigating the fabrication of microparticles for vaccine delivery using supercritical fluid technology.
Jag remains a part-time member of Nanopharm Ltd, an Aptar Pharma Company as Vice President of Science and Technology.

  • Next: 4 Jun 2024 Live online
  • Also: 8 Oct 2024 Live online

Delivery of Biologics to the Nasal Cavity

Live online

The nasal cavity is an established pathway to treat local diseases as well as systemic conditions using small molecules. As the pharmaceutical industry shifts towards targeted biologics, the nasal cavity is also an attractive target for delivery of peptides, monoclonal antibodies, nucleic acids and stem cells. This is an ideal opportunity to hear from experts in the field of nasal drug delivery who will address topics such as: challenges associated with formulation, barriers to cell penetration and absorption, the pros and cons for liquid versus powder formulations, and strategies for maintaining stability and prolonging retention in the nasal cavity.

  • 3 CPD hours Focused
  • Presented by Dr Jag Shur